对耶氏肺孢子菌肺炎患者进行复方磺胺甲(噁)唑治疗药物监测的重要性研究OACSTPCD

Pneumocystis jiroveci pneumonia(PJP)is one of the more common and serious opportunistic infections in patients with human immunodeficiency virus(HIV).With the use of immunosuppressants and chemotherapy drugs,most PJP cases reported in China are non-HIV immunosuppressed patients.Compound sulfamethoxazole(SMZco)is the first-line drug for the treatment of PJP,and there are wide individual differences in its pharmacokinetics.Through citing a PJP case treated with SMZco under drug monitoring,a systematic review was conducted from the aspects of SMZco pharmacokinetics,dose-related adverse reactions,and optimal therapeutic dose research.It aims to demonstrate the importance of drug monitoring for sulfamethoxazole therapy,which ensures the drug reaches effective therapeutic concentrations and the occurrence of its'adverse reactions was reduced.